STROBE Statement—checklist of items that should be included in reports of observational studies

Section/item	Item No	Recommendation	Reported on Page Number/Line Number	Reported on Section/Paragraph
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	Page 3/Line 34	Abstract/Paragraph 1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	Page 4/Lines 53-55	Abstract/ Paragraph 4
Introduction				
Background/ rationale	2	Explain the scientific background and rationale for the investigation being reported	Page 5-6/Lines 61-94	Introduction/Paragraph 1-5
Objectives	3	State specific objectives, including any prespecified hypotheses	Page 6/Lines 91-94	Introduction/Paragraph 5
Methods				
Study design	4	Present key elements of study design early in the paper	Page 6/Lines 98-100	Patients and Methods/Paragraph 1
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	Page 6-7/Lines 100-108	Patients and Methods/Paragraph 1-2
Participants	6	(a) ***Cohort study***—Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up ***Case-control study***—Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls ***Cross-sectional study***—Give the eligibility criteria, and the sources and methods of selection of participants	Page 6-7/Lines 100-108	Patients and Methods/Paragraph 1-2
		(b) ***Cohort study***—For matched studies, give matching criteria and number of exposed and unexposed ***Case-control study***—For matched studies, give matching criteria and the number of controls per case	N/A.	We did not perform matching analysis.
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	Page 8/Lines 136-142	Patients and Methods/Paragraph 10
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	N/A.	All variables were collected by manual review of the medical records.
Bias	9	Describe any efforts to address potential sources of bias	Page 7/Lines 104-108. We validated the treatment effect in an independent dataset.	Patients and Methods/Paragraph 2
Study size	10	Explain how the study size was arrived at	Page 6/Lines 98-100; Page 7/Lines 107-108	Patients and Methods/Paragraph 1-2
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	N/A.	Quantitative variables were shown as descriptive analysis in the Result section.

Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	Pages 8-9/Lines 144-152	Patients and Methods/Paragraph 11
		(b) Describe any methods used to examine subgroups and interactions	N/A.	We did not perform subgroup analysis due to the small sample size and low events rate.
		(c) Explain how missing data were addressed	Page 9/Lines 149-151	Patients and Methods/Paragraph 11
		(d) ***Cohort study***—If applicable, explain how loss to follow-up was addressed ***Case-control study***—If applicable, explain how matching of cases and controls was addressed ***Cross-sectional study***—If applicable, describe analytical methods taking account of sampling strategy	N/A.	Our study was a cohort study in design but did not include follow-up. We observed the perioperative outcomes.
		(e) Describe any sensitivity analyses	N/A.	We did not perform any sensitivity analyses because we found that little conditions could be modified.
Results				
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	Page 9/Lines 156-160	Results/Paragraph 1
		(b) Give reasons for non-participation at each stage	Page 9/Figure 159-160	Results/Paragraph 1
		(c) Consider use of a flow diagram	Page 9/Line 159-160	Results/Paragraph 1
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	Page 9/Lines 161-169	Results/Paragraph 2
		(b) Indicate number of participants with missing data for each variable of interest	Page 9/159-160-Figure 1	Results/Paragraph 1
		(c) ***Cohort study***—Summarise follow-up time (eg, average and total amount)	N/A.	We did not include follow-up data.
Outcome data	15*	***Cohort study***—Report numbers of outcome events or summary measures over time	Page 10/Line 174	Results/Paragraph 3
		Case-control study—Report numbers in each exposure category, or summary measures of exposure	N/A.	It is a cohort study.
		Cross-sectional study—Report numbers of outcome events or summary measures	N/A.	It is a cohort study.
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	Page 10/Lines 179-184	Results/Paragraph 5
		(b) Report category boundaries when continuous variables were categorized	N/A.	Continuous variables were not categorized in our study
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	N/A.	We calculated the relative risk between groups.

Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	N/A.	We did not perform subgroups, interactions, or any sensitivity analyses.
Discussion				
Key results	18	Summarise key results with reference to study objectives	Pages 11-12/Lines 210-216	Discussion/Paragraph 1
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	Page 14/Lines 264-267	Discussion/Paragraph 5
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	Page 12-13/Lines 217-252	Discussion/Paragraph 2-3
Generalisability	21	Discuss the generalisability (external validity) of the study results	Page 14/Lines 258-261. External validity was tested in an independent dataset.	Discussion/Paragraph 4
Other information				
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	Page 15/Lines 273-274	Acknowledgements/Paragraph 1

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.

Article information: https://dx.doi.org/10.21037/jtd-22-591
*As the checklist was provided upon initial submission, the page number/line number reported may be changed due to copyediting and may not be referable in the published version.
In this case, the section/paragraph may be used as an alternative reference.